INTERIM RESULTS OF PHASE 2 STUDY TO EVALUATE PI3K/MTOR INHIBITOR PAXALISIB (GDC-0084) GIVEN TO NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS WITH UNMETHYLATED O-6-METHYLGUANINE-METHYLTRANSFERASE PROMOTER-MedSci.cn

INTERIM RESULTS OF PHASE 2 STUDY TO EVALUATE PI3K/MTOR INHIBITOR PAXALISIB (GDC-0084) GIVEN TO NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS WITH UNMETHYLATED O-6-METHYLGUANINE-METHYLTRANSFERASE PROMOTER

Wen, P; de Groot, J; Battiste, J; Goldlust, S; Damek, D; Garner, J; Simpson, J; Olivero, A; Cloughesy, T

NEURO-ONCOLOGY, 2020; 22 (): 52

科室
- - 订阅+
  - 更多科室
工具
服务